Ovarian Cancer

David O'Malley, MD, discusses the increased benefit of rucaparib maintenance in patients with ovarian cancer who express RAD51C/D mutations.

Elizabeth M. Swisher, MD, discusses the implications of the phase III VELIA/GOG-3005 trial in ovarian cancer.

David O’Malley, MD, discusses the rationale to evaluate the clinical benefit of rucaparib maintenance treatment following disease progression in a subgroup of patients with ovarian cancer whose disease is associated with a mutation in a non-BRCA homologous recombination gene in the phase III ARIEL3 trial in ovarian cancer.

Pazopanib plus oral cyclophosphamide is a well-tolerated regimen that has clinically relevant benefit in patients with platinum-resistant or -refractory epithelial ovarian cancer, according to results from a retrospective study published in the Journal of Clinical Oncology.

John T. Comerci, MD, associate professor, University of Pittsburgh School of Medicine, and director of Gynecologic Oncology, University of Pittsburgh Medical Center Passavant Hospital, discusses the use of laparoscopy in ovarian cancer.

The combination of olaparib and bevacizumab was found to improve progression-free survival outcomes versus bevacizumab alone as a frontline maintenance treatment in patients with newly diagnosed advanced high-grade serous ovarian cancer, regardless of the timing of surgery or residual disease status after surgery.

The combination of niraparib and bevacizumab as a frontline maintenance therapy was found to have impressive clinical activity in patients with advanced ovarian cancer who had a complete or partial response to frontline platinum-based chemotherapy plus bevacizumab.

Michelle M. Boisen, MD, discusses the scoring system for optimal debulking in ovarian cancer.

Casey M. Cosgrove, MD, discusses the utilization of PARP inhibition in ovarian cancer.

Trametinib monotherapy has emerged as a new treatment option for women with recurrent low-grade serous ovarian cancers based on improvements in survival outcomes and response rates demonstrated in a phase II/III study.

Michelle M. Boisen, MD, discusses criteria for selecting patients with ovarian cancer for upfront surgery versus neoadjuvant chemotherapy.

Adding veliparib to frontline induction chemotherapy increased complete and CA-125 responses compared with chemotherapy alone in patients with high-grade serous ovarian cancer, according to an exploratory analysis of the phase III VELIA trial.

Dana Chase, MD, discusses niraparib as frontline maintenance therapy in ovarian cancer.

Rucaparib was associated with superior outcomes among women with ovarian cancer harboring a non-BRCA homologous recombination repair gene mutation compared with placebo, according to an analysis of specimens collected in the phase III ARIEL3 trial (NCT01968213).

Alexander B. Olawaiye, MD, discusses the role of surgery in women with newly diagnosed ovarian cancer.

The anti-DLL4/VEGF bispecific antibody navicixizumab showed promising clinical activity when used in combination with paclitaxel in heavily pretreated patients with platinum-resistant ovarian cancer.

Kathleen Moore, MD, discusses the early phase data that led to the development of the phase III FORWARD I/ GOG 3011 trial in ovarian cancer.

Frontline maintenance treatment with Vigil immunotherapy demonstrated an improvement in relapse-free survival compared with placebo in patients with stage III/IV ovarian cancer, especially in those with BRCA1/2 wild-type disease.

Elizabeth M. Swisher, MD, discusses how the phase III VELIA/GOG-3005 trial compares with other trials examining up-front maintenance therapy in ovarian cancer.

Veliparib plus chemotherapy extended progression-free survival for BRCA wild-type patients with high-grade serous carcinoma.

The investigational antibody-drug conjugate anetumab ravtansine showed promising antitumor activity in heavily pretreated patients with mesothelin-expressing solid tumors.

An independent panel determined that the investigational agent VB-111 met the interim prespecified efficacy criterion in the phase III OVAL study in patients with platinum-resistant ovarian cancer, and that the trial should continue without modification.

Cediranib plus olaparib did not lead to a statistically significant improvement in progression-free survival compared with platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer.

In our exclusive interview, Dr. Markman shares the reasons why he dove into the gynecologic cancer space, what mottos he lives by in daily practice, and patient cases that have significantly impacted his career.

Mira Hellmann, MD, discusses the impact of surgery on patients with ovarian cancer.